For UA/NSTEMI patients in whom PCI has been selected as a postangiography management strategy, the instructions noted below should be followed: modified ( thienopyridine replaced with P2Y12 receptor inhibitor ). a. Continue aspirin.61,63,64 (Level of Evidence: A) b. Administer a loading dose of a P2Y12 receptor inhibitor if not started before diagnostic angiography.9,68,74,101 103 (Level of Evidence: A) c. Discontinue anticoagulant therapy after PCI for uncomplicated cases.80,82,104 106 (Level of Evidence: B) 5. For UA/NSTEMI patients in whom medical therapy is selected as a management strategy and in whom no significant obstructive coronary artery disease on angiography was found, antiplatelet and anticoagulant therapy should be administered at the discretion of the clinician (Level of Evidence: C). For patients in whom evidence of coronary atherosclerosis is present (eg, luminal irregularities or intravascular ultrasound-demonstrated lesions), albeit without flow-limiting stenoses, long-term treatment with aspirin and other secondary prevention measures should be prescribed. (Level of Evidence: C) 2007 recommendation remains current. 6. For UA/NSTEMI patients in whom medical therapy is selected as a management strategy and in whom coronary artery disease was found on angiography, the following approach is recommended: modified (included ticagrelor). a. Continue aspirin.61,63,64 (Level of Evidence: A) b. Administer a loading dose of clopidogrel or ticagrelor* if not given before diagnostic angiography.9,13 (Level of Evidence: B) c. Discontinue IV GP IIb/IIIa inhibitor if started previously.50,51,57,107 (Level of Evidence: B) (Continued) Table 3. Continued 2012 Focused Update Recommendations 2012 Comments d. Anticoagulant therapy should be managed as follows: 1. Continue IV UFH for at least 48 hours or until discharge if given before diagnostic angiography66,79,80 (Level of Evidence: A) 2. Continue enoxaparin for duration of hospitalization, up to 8 days, if given before diagnostic angiography.80 82,96 (Level of Evidence: A) 3. 